Skip to main content
Shivalik Rasayan Ltd. logo

Shivalik Rasayan Ltd. — Investor Relations & Filings

Ticker · SHIVALIK ISIN · INE788J01021 LEI · 335800FEB4CFANKSV783 BSE.NS Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2026-05-27 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SHIVALIK

About Shivalik Rasayan Ltd.

https://shivalikrasayan.com/

Shivalik Rasayan Ltd. is a diversified chemical and pharmaceutical manufacturer specializing in the production of organophosphorus-based agrochemicals and high-potency active pharmaceutical ingredients (APIs). The company operates through two primary business segments: Agrochemicals and Pharmaceuticals. In the agrochemical sector, it is a leading producer of technical-grade insecticides, including Dimethoate and Malathion. Its pharmaceutical division focuses on the development and manufacture of oncology APIs and finished dosage forms, utilizing advanced research and development capabilities to serve global markets. Shivalik Rasayan maintains state-of-the-art manufacturing facilities designed to meet international regulatory standards, positioning itself as a key supplier of specialized chemical intermediates and complex therapeutic solutions for the healthcare and agricultural industries.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is the outcome of a board meeting under SEBI LODR Regulation 33 and contains the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026, complete with detailed P&L, segment reporting, assets & liabilities – i.e., substantive financial statements. This is not a full annual report (10-K) and includes actual financial data, so it fits the Interim/Quarterly Report category. FY 2026
2026-05-27 English
We wish to inform you that the Board of Directors of the Company approved the financial results for the quarter and year ended on 31.03.2026
Regulatory Filings Classification · 60% confidence The document is a formal stock‐exchange filing under SEBI LODR, titled “Outcome of Board Meeting.” It is addressed to BSE & NSE, reports that the Board has approved the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, and attaches detailed tables and the auditor’s report. It also covers dividend recommendation, auditor appointments, and director resignation. This is not a full Annual Report (10-K) or a standalone Audit Report, nor is it a simple notice of publication—it is a regulatory announcement under listing regulations. There is no specific category for “Board Meeting Outcome,” so it falls into Regulatory Filings (RNS).
2026-05-27 English
This is to inform you that Mr. Sanjay Bansal Non- Executive Director of the Company has resigned from his Directorship due to personal reasons, which has been accepted by the management ....
Board/Management Information Classification · 96% confidence The document is a formal regulatory intimation under SEBI (Listing Obligations and Disclosure Requirements) about the resignation of a Non-Executive Director, including details required by Regulation 30 and SEBI Circular. It is an announcement of a change in the company’s board of directors, fitting the Board/Management Information category.
2026-05-27 English
We hereby inform that the Board of Directors of the Company recommended a final dividend @ 10% on Equity Shares of Rs. 5/- each i.e. 50 paise per share for the financial year 2025-26 subject ....
Interim / Quarterly Report Classification · 85% confidence The document is a formal ‘Outcome of Board Meeting’ filing under SEBI LODR that includes the audited financial results (Statement of Profit & Loss, segment-wise revenue, assets & liabilities, notes) for the quarter and year ended March 31, 2026. It contains full financial statements rather than just highlights, and is not a full Annual Report (10-K) but rather the quarterly/year-to-date interim results. Therefore it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-27 English
We wish to inform that the Board approved the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended on 31.03.2026
Earnings Release Classification · 85% confidence The document is the formal stock‐exchange filing titled “Outcome of Board Meeting” in which the company’s board approves the audited financial results (standalone and consolidated) for Q4 and the full year ended March 31, 2026. It includes detailed financial statements (Annexure A & B), the audit report (Annexure C), dividend recommendation, and board/committee changes. While it is not a full annual report (10–K) and contains substantive financial data rather than mere highlights, it represents the initial announcement of periodic financial results to investors and regulators. Therefore it best fits the Earnings Release category. FY 2026
2026-05-27 English
We wish to inform you that the Board of Directors of the Company approved the Audited Financial results (Standalone & Consolidated) for the quarter and year ended on 31.03.2026
Interim / Quarterly Report Classification · 90% confidence The document is the official stock exchange filing under SEBI LODR Regulation 33 providing audited financial results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, along with the detailed income statements, segment reporting, and statement of assets & liabilities. It also includes Board resolutions (dividend recommendation, auditor appointments, director resignation). It is not a full annual report (10-K) nor merely an earnings highlight—rather it is the detailed quarterly/year-end financial report itself. Therefore, it falls under Interim / Quarterly Report (IR). FY 2026
2026-05-27 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.